X

Xenon Pharmaceuticals Inc
F:XP0

Watchlist Manager
Xenon Pharmaceuticals Inc
F:XP0
Watchlist
Price: 28 EUR 1.45% Market Closed
Market Cap: 2.1B EUR

Relative Value

The Relative Value of one XP0 stock under the Base Case scenario is 6.38 EUR. Compared to the current market price of 28 EUR, Xenon Pharmaceuticals Inc is Overvalued by 77%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

XP0 Relative Value
Base Case
6.38 EUR
Overvaluation 77%
Relative Value
Price
X
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
11
vs Industry
9
Median 3Y
90.5
Median 5Y
33
Industry
7.5
Forward
345.5
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-16.6
Industry
23.6
Forward
-7.8
vs History
vs Industry
Median 3Y
-19.9
Median 5Y
-19.9
Industry
20.2
vs History
vs Industry
Median 3Y
-19.5
Median 5Y
-18.2
Industry
22.9
vs History
33
vs Industry
28
Median 3Y
3.6
Median 5Y
3.3
Industry
2.8
vs History
11
vs Industry
9
Median 3Y
53.2
Median 5Y
20
Industry
7.7
Forward
268.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-10.9
Industry
4.9
Forward
-5.6
vs History
vs Industry
Median 3Y
-10.7
Median 5Y
-10.8
Industry
4.9
Forward
-5.5
vs History
vs Industry
Median 3Y
-15.2
Median 5Y
-14.6
Industry
5.4
vs History
vs Industry
Median 3Y
-14.9
Median 5Y
-13.9
Industry
4
vs History
84
vs Industry
17
Median 3Y
12.5
Median 5Y
14.7
Industry
5.1

Multiples Across Competitors

XP0 Competitors Multiples
Xenon Pharmaceuticals Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Xenon Pharmaceuticals Inc
F:XP0
2.5B EUR 328.9 -9.8 -6.6 -6.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 905 135.8 -161 146.1 -195 682.7 -193 449.8
US
Abbvie Inc
NYSE:ABBV
339.9B USD 5.9 81.8 15.5 23
US
Amgen Inc
NASDAQ:AMGN
158.8B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136.5B USD 4.8 22.9 10 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD 10.9 -121.8 25.9 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 077.8 -530.2 -577.3 -561.9
AU
CSL Ltd
ASX:CSL
116.7B AUD 5 27.9 17.2 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.4B USD 4.4 13.7 12.2 13.7
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.4 -66.2 -59.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41B USD 17.5 -152.2 -682.1 -341.8
P/S Multiple
Revenue Growth P/S to Growth
CA
X
Xenon Pharmaceuticals Inc
F:XP0
Average P/S: 3 082 510.5
328.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 905 135.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 077.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
4%
1.1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.5
30%
0.6
P/E Multiple
Earnings Growth PEG
CA
X
Xenon Pharmaceuticals Inc
F:XP0
Average P/E: 34.6
Negative Multiple: -9.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 146.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -121.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -152.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
X
Xenon Pharmaceuticals Inc
F:XP0
Average EV/EBITDA: 15.9
Negative Multiple: -6.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 682.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -682.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
X
Xenon Pharmaceuticals Inc
F:XP0
Average EV/EBIT: 20.5
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 449.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -341.8 N/A N/A